drugset / Trial / NCT05813561

The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis

NCT05813561

Phase 3 Completed 332 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.

Timeline

Start
2021-12-30
Primary completion
2022-07-23
Completion
2023-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule 40 mg

Indications